Lung Cancer Clinical Trial
Official title:
Applicability of Respiratory Tele-physiotherapy in the Preoperative Context of Thoracic Surgery at the Hospital de la Santa Creu y Sant Pau (HSCSP).
Verified date | August 2022 |
Source | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The home confinement caused by the COVID-19 pandemic has aroused the need to use telematic communication systems to provide remote treatments. More and more research is being done on preoperative respiratory physiotherapy in patients undergoing thoracic surgery with lung cancer. It is a treatment that has great relevance in the prevention of postoperative complications and in the quality of life of the patient. Therefore, this study is proposed to highlight the applicability of a telematic system of preoperative physiotherapy treatment with the FISSIOS application at the Hospital de la Santa Creu i Sant Pau (HSCSP).
Status | Completed |
Enrollment | 8 |
Est. completion date | August 23, 2022 |
Est. primary completion date | August 23, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients aged 18-> 80 years. Candidates for CP resection with curative intent, either for VATS or thoracotomy, which meet the ppo-DLCO> 35% and ppo-FEV1> 35% surgical criteria, who agree to participate and sign the informed consent Exclusion Criteria: - Patients undergoing tumor resection for cancer requiring pneumonectomy, with cognitive impairment, which are outside the area of influence of the HSCSP or which do not have from an Android / iPhone Operating System (iOS) device. It is also considered an exclusion criterion not fulfilling 50% of the predefined time of the program (a week and a half) and surgical. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feability to implement a respiratory tele-physiotherapy program in patients diagnosed with Cancer Pulmonary candidates for thoracotomy or VATS at the Hospital de la Santa Creu i Sant Pau. | will be assessed over time of treatment. 80% compliance with treatment. | 1-4 weeks | |
Secondary | Adherence with treatment time -minutes of treatment | we will collect them with the minutes of treatment that appear in the application | 1-4 weeks | |
Secondary | The capacity of effort- 6MWT (6 meters walking test) | the capacity of effort with the 6 minutes walking test Evaluate the capacity of effort before and after the tele-physiotherapy program in patients undergoing thoracic surgery diagnosed with lung cancer | 1-4 weeks | |
Secondary | Dyspnea- mMRC (modified Medical Research Council) | Dyspnea in activities of daily living before and after the program with mMRC. 0 Absence of dyspnea on intense exercise
1 Dyspnea when walking fast on level ground, or when walking up a slight incline. pronounced. two Dyspnea causes you to be unable to keep up with other people in the same age walking on level ground or having to stop to rest when walking on level ground at your own pace. 3 Dyspnea makes you have to stop to rest after walking 100 meters or a few minutes after walking on the flat. 4 Dyspnea prevents the patient from leaving the house or appears with activities such as dressing or undress. tele-physiotherapy performed on patients diagnosed with CP who are candidates for surgery thoracic. |
1-4 weeks | |
Secondary | Quality of Life Questionnaire module for Lung Cancer patients QLQ-C30 | the evolution of health-related quality of life before and after the program with EORTC QLQ-C30.
Quality of Life Questionnaire module for Lung Cancer patients QLQ-C30: All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. QLQ-LC 13: All of the scales and single item measures range in score from 0 to 100. A high score for the symptom scales / single items represents a high level of symptomatology or problems. |
1-4 weeks | |
Secondary | Quality of Life Questionnaire module for Lung Cancer patients QLQ-LC 13 | the evolution of health-related quality of life before and after the program with Quality of Life Questionnaire module for Lung Cancer patientsQLQ-LC 13.
QLQ-LC 13: All of the scales and single item measures range in score from 0 to 100. A high score for the symptom scales / single items represents a high level of symptomatology or problems. |
1-4 weeks | |
Secondary | Anxiety and depression | the evolution of the degree of anxiety and depression before and after of the program.
Each question is scored from 0-3. There are 14 questions of which 7 assess depression and 7 assess anxiety. Scoring: 0-7 Normal, 8-10 Borderline abnormal (borderline case), 11-21 Abnormal (case). |
1-4 weeks | |
Secondary | degree of satisfaction- satisfaction questionnaire | the degree of satisfaction of the program after the program. There are 2 closed questions and a question and a satisfaction rating of 0-10. 0 is the minimum satisfaction and 10 is the maximum satisfaction | 1-4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|